References
- Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J et al. Estrogen receptors: How do they signal and what are their targets. Physiol Rev 2007;87:905–931.
- Buch I, Giorgino T, De Fabritiis G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci USA 2011;108:10184–10189.
- Genheden S, Nilsson I, Ryde U. Binding affinities of factor Xa inhibitors estimated by thermodynamic integration and MM/GBSA. J Chem Inf Model 2011;51:947–958.
- Gilson MK, Zhou HX. Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 2007;36:21–42.
- Fidelak J, Juraszek J, Branduardi D, Bianciotto M, Gervasio FL. Free-energy-based methods for binding profile determination in a congeneric series of CDK2 inhibitors. J Phys Chem B 2010;114:9516–9524.
- Lyne PD, Lamb ML, Saeh JC. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 2006;49:4805–4808.
- Guimarães CR, Cardozo M. MM-GB/SA rescoring of docking poses in structure-based lead optimization. J Chem Inf Model 2008;48:958–970.
- Shen J, Tan C, Zhang Y, Li X, Li W, Huang J et al. Discovery of potent ligands for estrogen receptor β by structure-based virtual screening. J Med Chem 2010;53:5361–5365.
- Tuccinardi T, Bertini S, Martinelli A, Minutolo F, Ortore G, Placanica G et al. Synthesis of anthranylaldoxime derivatives as estrogen receptor ligands and computational prediction of binding modes. J Med Chem 2006;49:5001–5012.
- Collini MD, Kaufman DH, Manas ES, Harris HA, Henderson RA, Xu ZB et al. 7-Substituted 2-phenyl-benzofurans as ERβ selective ligands. Bioorg Med Chem Lett 2004;14:4925–4929.
- Edsall RJ Jr, Harris HA, Manas ES, Mewshaw RE. ERβ ligands. Part 1: The discovery of ERβ selective ligands which embrace the 4-hydroxy-biphenyl template. Bioorg Med Chem 2003;11:3457–3474.
- Yang C, Edsall R Jr, Harris HA, Zhang X, Manas ES, Mewshaw RE. ERβ ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg Med Chem 2004;12:2553–2570.
- Maestro, Version 9.0, Schrödinger, LLC, New York, NY, 2009.
- Ligprep, Version 2.3, Schrödinger, LLC, New York, NY, 2009.
- Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608–4618.
- Prime, Version 2.1, Schrödinger, LLC, New York, NY, 2009.
- Impact, Version 5.5, Schrödinger, LLC, New York, NY, 2009.
- Glide, Version 5.5, Schrödinger, LLC, New York, NY, 2009.
- Thompson MA (2004) ArgusLab 4.0.1. Planaria Software LLC, Seattle, WA.
- Strike, 1.8, Schrödinger, LLC, New York, NY, 2009.
- Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. J Med Chem 2006;49:5851–5855.
- Tirado-Rives, Jorgensen WL. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J Med Chem 2006;49:5880–5884.
- Coupez B, Lewis RA. Docking and scoring–theoretically easy, practically impossible? Curr Med Chem 2006;13:2995–3003.
- Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M et al. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem 2006;281:17909–17919.
- Guimarães CR, Mathiowetz AM. Addressing limitations with the MM-GB/SA scoring procedure using the WaterMap method and free energy perturbation calculations. J Chem Inf Model 2010;50:547–559.